Provided by Tiger Fintech (Singapore) Pte. Ltd.

Marinus Pharmaceuticals

0.5500
+0.0000
Volume:- -
Turnover:605.61K
Market Cap:30.35M
PE:-0.22
High:0.5500
Open:0.5500
Low:0.5500
Close:0.5500
Loading ...

JMP Securities Downgrades Marinus Pharmaceuticals to Market Perform from Outperform

MT Newswires Live
·
25 Oct 2024

Marinus Pharmaceuticals' Oral Seizure Drug Disappoints In Late-Stage Study, Appoints Advisor To Explore Options

Benzinga
·
25 Oct 2024

Marinus (MRNS) was downgraded to a Hold Rating at JMP Securities

TIPRANKS
·
24 Oct 2024

Marinus Pharmaceuticals downgraded to Hold from Buy at Truist

TIPRANKS
·
24 Oct 2024

Marinus Pharmaceutical Shares Plumb New Depths After Study Failure

Dow Jones
·
24 Oct 2024

Dow Falls 150 Points; Tesla Posts Upbeat Earnings

Benzinga
·
24 Oct 2024

Marinus Pharmaceuticals Is Maintained at Buy by EF Hutton

Dow Jones
·
24 Oct 2024

Marinus Pharmaceuticals Shares Down 70% After Rare Disease Drug Fails Late-Stage Trial

THOMSON REUTERS
·
24 Oct 2024

Marinus tanks after late stage trial for treatment of seizures in TSC fails to meet main goal

seekingalpha
·
24 Oct 2024

BUZZ-Marinus plummets after discontinuing development of rare disease drug

Reuters
·
24 Oct 2024

Marinus Pharmaceuticals Shares Down 67% Premarket After Rare Disease Drug Fails Late-Stage Trial

THOMSON REUTERS
·
24 Oct 2024

Marinus Pharma to explore options as rare disease drug fails trial

Reuters
·
24 Oct 2024

Marinus Pharmaceuticals Inc - Discontinues Ganaxolone Development, Reduces Workforce

THOMSON REUTERS
·
24 Oct 2024

Marinus Pharmaceuticals Announces Topline Results From Phase 3 Trusttsc Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives

THOMSON REUTERS
·
24 Oct 2024

Marinus Pharmaceuticals Inc - Trial Did Not Meet Primary Endpoint of Seizure Frequency Change

THOMSON REUTERS
·
24 Oct 2024

Marinus Pharmaceuticals Inc: Cost Reduction Activities Are Underway

THOMSON REUTERS
·
24 Oct 2024